ESR1 and ovarian cancer: Moreover, such pathways as IL-8, ovarian cancer and estrogen receptor signalling pathways, previously described to be deregulated upon inhibition of DOT1L alone [4] or in combination with menin pharmacological blockade in other biological contexts [11] were also influenced.